Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 25 April at 4:30pm because of system upgrades. We expect to open them again on Friday 26 April at 8am the latest.

ArgusEye - driving the revolution in manufacturing of biopharmaceuticals

Reference number
Coordinator ArgusEye AB
Funding from Vinnova SEK 500 000
Project duration May 2018 - June 2019
Status Completed

Purpose and goal

The overall objective of the project was to support and promote the commercialization of ArgusEye´s sensor systems by conducting an extensive market analysis and develop a comprehensive business plan. The planned activities have been fully implemented and the project has generated significant insights that will form the basis for strategic decisions in the continued commercialization process.

Expected results and effects

The project has resulted in a detailed business plan describing the potential market for ArgusEye’s sensor systems and a go-to-market strategy for a successful establishment on the market. A new prototype has also been developed that will be used in the next phase of our commercialization plan which includes an extensive technical validation in a relevant bioproduction process with selected industrial partners.

Planned approach and implementation

All activities carried out during the course of the project, i.e. market analysis, business plan development and prototype production have been made in collaboration with professional specialists in their respective areas. These collaborations have been very rewarding as they have made the work process more efficient and resulted in increased knowledge in the different fields.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 6 March 2019

Reference number 2018-02219

Page statistics